Executive summary
United States Patent 12,005,051 is directed to improving therapeutic outcome from topical roflumilast under nonadherence conditions, defined operationally as a patient missing ≥1 dose but ≤2 consecutive doses while maintaining systemic exposure using a specific topical excipient system (notably diethylene glycol monoethyl ether plus a phosphate ester surfactant blend with dicetyl phosphate, ceteth-10 phosphate, and cetearyl alcohol). The claims are written to cover (i) treatment optimization based on pharmacokinetic retention (plasma concentration drop threshold), (ii) specific skin disease indications (atopic dermatitis; psoriasis), and (iii) formulation architecture (oil-in-water emulsion or foam; oil-in-water quantitative ranges; pH). The estate’s enforceability risk is tied to how strictly courts treat pharmacokinetic functional limitations (“decreases by less than 50%”) and to whether competing products practice the same excipient combination and concentration ranges.
What is US Patent 12,005,051 about and what do its claims cover?
Core invention in one line
A topical roflumilast regimen using a defined skin-applied excipient system so that, even if a patient misses one or two consecutive doses, roflumilast plasma concentration decreases by less than 50%, thereby improving therapeutic outcome.
Claim 1: baseline method scope (nonadherence + PK threshold + defined composition)
Claim 1 is the broad anchor. It requires all elements:
- Method for improving therapeutic outcome of treatment with roflumilast.
- Topically administer once daily a composition comprising:
- Diethylene glycol monoethyl ether
- Cetearyl alcohol
- Dicetyl phosphate
- Ceteth-10 phosphate
- Roflumilast
- Patient dosing behavior: patient misses at least one dose but no more than two consecutive doses.
- Functional pharmacokinetic limitation: plasma concentration of roflumilast decreases by <50%.
This claim is not merely formulation-only. It is method-of-use with an exposure retention requirement.
Claim 2 and Claim 13: indication narrowing
- Claim 2: patient has atopic dermatitis.
- Claim 13: patient has psoriasis.
Indication limitations narrow infringement to those marketed or used for those dermatologic conditions (depending on how the proof is developed in litigation).
Claim 3 and Claim 5: timing-specific PK limitations
- Claim 3: after three days of missed dosing, plasma concentration decreases by <50%.
- Claim 5: patient misses two consecutive doses, plasma concentration decreases by <50%.
These create narrower routes to infringement and give litigators multiple timepoints for comparing clinical or bridging PK data.
Claim 4: exemplar formulation with quantitative excipient composition and pH
Claim 4 fixes an explicit formulation:
- Roflumilast 0.3% w/w
- White petrolatum 10.0% w/w
- Isopropyl palmitate 5.0% w/w
- Cetearyl alcohol 10.0% w/w
- Dicetyl phosphate 10.0% w/w
- Ceteth-10 phosphate 25.0% w/w
- Diethylene glycol monoethyl ether 25.0% w/w
- Methylparaben 0.2% w/w
- Propylparaben 0.05% w/w
- Purified water q.s. ad 100
- pH adjusted to 5.5
This claim supports argument that the patent is not limited to abstract classes of surfactants and aliphatic solvents, but includes a specific recipe.
Claim 6: half-life limitation
- Claim 6: roflumilast half-life about 81–89 hours.
This is another functional tie between formulation and systemic exposure dynamics.
Claim 8 and Claim 9: add-on therapy vehicle compatibility
- Claim 8: further active agent selected from a broad list (topical immunomodulators, keratolytics, antimetabolites, steroids, biologics listed, etc.).
- Claim 9: if corticosteroid, selected from a large sub-list; if vitamin D analogue, calcipotriene and calcitriol.
From an infringement standpoint, these dependent claims can matter if an accused regimen uses combination therapy consistent with these lists.
Claim 10: dosage form architecture
- Composition selected from oil-in-water emulsion and foam.
This is relevant to design-around because it narrows the acceptable product types.
Claims 11–12: roflumilast concentration ranges
- 0.05–1% w/w (Claim 11)
- 0.1–0.5% w/w (Claim 12)
These ranges define formulation boundaries.
Claims 14, 16–19: quantitative excipient ranges
- Diethylene glycol monoethyl ether in 10–30% w/w (Claim 14)
- Phosphate ester surfactant blend in 1–25% w/w (Claim 16)
- 2.5–20% w/w (Claim 17)
- 5–15% w/w (Claim 18)
- Diethylene glycol monoethyl ether 10–30% w/w (Claim 19)
- Water 49.45% (Claim 20), dependent on Claim 4’s structural template.
How broad are the claims: excipient coverage vs. functional plasma exposure limitations?
Two layers of scope operate together:
-
Composition layer (structural excipient requirement)
The patent requires presence of:
- diethylene glycol monoethyl ether
- cetearyl alcohol
- dicetyl phosphate
- ceteth-10 phosphate
- roflumilast
-
Method and exposure layer (functional pharmacokinetic threshold)
The method is defined by outcomes under nonadherence:
- missing at least one dose but no more than two consecutive doses
- plasma concentration decrease threshold (<50%)
- optionally specific timepoint (three days) and specific miss pattern (two consecutive doses)
- optional systemic parameter (half-life 81–89 hours)
Why this matters for claim construction
- The functional limitation can narrow infringement even if excipients match. If an accused product matches the excipient set but produces different systemic exposure dynamics under “missed dose” conditions, it may fall outside the literal scope.
- Conversely, the claims’ reliance on plasma concentration creates litigation pressure to test or model exposure under regimen discontinuity, which can become an evidentiary battleground.
What formulations are protected by US Patent 12,005,051 (ranges, pH, and dosage forms)?
Protected composition types
- Oil-in-water emulsion
- Foam
(Claim 10)
Roflumilast concentration bands
- 0.05–1% w/w (Claim 11)
- 0.1–0.5% w/w (Claim 12)
- A specific exemplar at 0.3% w/w (Claim 4)
Key excipient concentration bands
- Diethylene glycol monoethyl ether: 10–30% w/w (Claims 14, 19)
- Phosphate ester surfactant blend:
- 1–25% w/w (Claim 16)
- 2.5–20% w/w (Claim 17)
- 5–15% w/w (Claim 18)
Specific exemplar formulation conditions
Quantitative composition detail in Claim 4 and Claim 20
- Claim 4 sets the full composition and pH.
- Claim 20 pins water at 49.45% (dependent on Claim 4).
Which indications (atopic dermatitis, psoriasis) are covered and how does claim scope change by disease?
Freestanding structural scope exists in Claim 1 (method improving therapeutic outcome of topical roflumilast under missed doses). Indication-dependent claims add market-specific hooks:
- Atopic dermatitis (Claim 2)
- Psoriasis (Claim 13)
Practical impact
Indication-dependent claims can be used when a defendant’s labeling, promotional materials, or real-world use data show the product is being applied for those conditions.
How do the “missed dose” and “plasma decrease <50%” limitations define infringement risk?
Regimen behavior trigger
- “misses at least one dose but no more than two consecutive doses”
This is an explicit, bounded nonadherence scenario.
Exposure retention threshold
- plasma concentration decreases by <50%
Dependent claims tighten the exposure definition:
- “after three days of missed dosing” (Claim 3)
- “misses two consecutive doses” (Claim 5)
- “half-life about 81–89 hours” (Claim 6)
Design-around logic
A competitor seeking to avoid literal infringement would likely target one of:
- Remove one of the mandated excipients (diethylene glycol monoethyl ether, dicetyl phosphate, ceteth-10 phosphate, cetearyl alcohol)
- Change the excipient concentrations such that the phosphate blend or diethylene glycol monoethyl ether no longer falls in the claimed ranges (for range-dependent claims)
- Achieve a different systemic exposure profile under missed dosing so that the plasma concentration decrease is ≥50%
How does the patent compare with typical roflumilast topical IP patterns (excipients vs. active-centric claims)?
Within topical dermatology IP, two common claim archetypes exist:
- Active-centric: method claims focused on pharmacology, dose timing, and indications.
- Vehicle-centric: formulation claims tied to excipient systems that modulate absorption, tolerability, and residence time.
US 12,005,051 is predominantly vehicle-centric but drafted with a systemic PK functional payoff. The patent’s novelty thrust is not “roflumilast treats X,” but “this topical vehicle makes roflumilast exposure persist enough that missed dosing does not depress plasma levels beyond a threshold.”
That claim strategy matters because it can extend protection beyond purely branded dosing instructions into product formulation defensibility.
What is the likely commercial and litigation leverage of these claim types?
Leverage points
- Functional clinical endpoint (plasma concentration decrease threshold) gives a measurable infringement criterion.
- Concentration ranges and specific exemplar formulation enable strong comparisons of accused products’ compositions.
- Dosage form restriction (oil-in-water emulsion or foam) reduces defense options if a product uses a different class of topical base.
Possible litigation friction
- Courts typically scrutinize functional limitations for clarity and proof. Here, the boundary (<50%) is specific, which can increase enforceability but also demands robust comparative PK evidence.
- If an accused product’s PK profile differs under discontinuation conditions, it can drive expert battles and testing.
Patent estate analysis: what else does the landscape likely need to include?
The input provided contains only the claims for US 12,005,051, not the rest of the estate or related patents. A full “landscape” requires at least:
- priority and filing dates,
- publication numbers and family members,
- prosecution history,
- listed assignees,
- continuation/divisional relationships,
- Orange Book or FDA reference product and listed patents,
- any Paragraph IV or other litigation involving roflumilast topical products.
Per the constraints, no additional landscape assertions are included because the required underlying patent and regulatory record is not provided.
Key claim-by-claim scope map (infringement elements checklist)
| Claim |
Required patient condition / regimen |
Composition constraints |
Exposure/PK limitations |
| 1 |
Misses 1 to 2 consecutive doses; once daily topical |
roflumilast + diethylene glycol monoethyl ether + cetearyl alcohol + dicetyl phosphate + ceteth-10 phosphate |
plasma decreases <50% |
| 2 |
Atopic dermatitis |
Same as claim 1 |
Same as claim 1 |
| 3 |
Missed dosing; after 3 days |
Same as claim 1 |
<50% after 3 days |
| 4 |
General |
Exact formulation with ranges fixed; pH 5.5 |
Inherits claim 1 PK rule |
| 5 |
Misses two consecutive doses |
Same as claim 1 |
<50% |
| 6 |
General |
Same as claim 1 |
half-life 81–89 hours |
| 7 |
Human |
Same as claim 1 |
Same as claim 1 |
| 8 |
General |
Same as claim 1 plus additional active agent (broad list) |
Same as claim 1 |
| 9 |
If corticosteroid or vitamin D analogue selected |
Same as claim 8 plus sub-class limitations |
Same as claim 1 |
| 10 |
General |
Oil-in-water emulsion or foam |
Same as claim 1 |
| 11 |
General |
roflumilast 0.05–1% w/w |
Same as claim 1 |
| 12 |
General |
roflumilast 0.1–0.5% w/w |
Same as claim 1 |
| 13 |
Psoriasis |
Same as claim 1 |
Same as claim 1 |
| 14 |
General |
diethylene glycol monoethyl ether 10–30% w/w |
Same as claim 1 |
| 15 |
General method with “phosphate ester surfactant blend” |
diethylene glycol monoethyl ether + phosphate ester blend + roflumilast |
missing dose condition + <50% |
| 16–18 |
General |
phosphate ester blend at 1–25% then 2.5–20% then 5–15% |
Same as claim 15 |
| 19 |
General |
diethylene glycol monoethyl ether 10–30% w/w |
Same as claim 15 |
| 20 |
General |
purified water 49.45% (dependent on claim 4) |
Same as claim 1 |
Key Takeaways
- US 12,005,051 protects a topical roflumilast method conditioned on nonadherence (missing 1 to 2 consecutive once-daily doses) with a defined systemic exposure retention requirement (plasma drop <50%).
- Claim scope hinges on a specific excipient package: diethylene glycol monoethyl ether + cetearyl alcohol + dicetyl phosphate + ceteth-10 phosphate, plus the active roflumilast.
- The patent strengthens enforceability with quantitative ranges (roflumilast, diethylene glycol monoethyl ether, phosphate blend) and a fixed exemplar formulation (including pH 5.5).
- Indication-dependent claims add targeted coverage for atopic dermatitis and psoriasis.
- Litigation risk for competitors is highest when their topical vehicle preserves the claimed excipient set and replicates the patented PK retention outcome under missed dosing.
FAQs
-
How can a generic developer test whether it meets the “plasma decrease <50%” limitation?
By generating comparative pharmacokinetic data designed around the patented nonadherence scenarios (missed dosing patterns) and assessing whether measured plasma roflumilast decreases are less than 50%.
-
Do the indication limits (atopic dermatitis, psoriasis) matter for infringement if the product is used off-label?
Indication-dependent claims require proof tied to the claimed conditions, making label and use evidence central to enforcement strategy.
-
What is the main formulation design-around lever for US 12,005,051?
Changing the excipient system so it lacks at least one of the required components (or falls outside concentration/range limitations) while also not achieving the patented plasma-retention outcome.
-
Are foam and oil-in-water emulsion both covered equally under the patent?
Claim 10 includes both dosage-form architectures, so either can fall within scope if other claim elements are met.
-
Can combination therapy affect infringement for this patent?
Yes, dependent claims explicitly include additional active agents from specified lists, so combination regimens may create additional infringement pathways.
References (APA)
(No references provided because only the patent claims text was supplied and no external patent/publication record was included.)
